Executive Summary: A President’s Perspective from the Tarmac
In a recently released communique, Dr. Kelly Shanahan, President of one of the nation’s leading metastatic research funding organizations, provided a transparent look into the grueling yet vital intersection of patient advocacy, clinical participation, and philanthropic leadership. Writing from an airport—a setting that has become a second home during a period of intense travel—Dr. Shanahan detailed the current state of the 2026 grant cycle, which has seen a record-breaking surge in interest from the scientific community.
The organization is currently navigating the review process for a historic number of Letters of Intent (LoIs), with a significant majority—75%—targeting the high-impact $450,000 translational award mechanism. Despite a global landscape marked by economic volatility, the organization has set a robust fundraising target of $3.75 million for the current fiscal year. This goal represents a calculated balance between the urgent need for life-extending research and the "realistic" constraints of modern charitable giving.
Main Facts: The Record-Breaking 2026 Grant Cycle
The core of the current organizational effort lies in the 2026 grant cycle. The "Letter of Intent" phase serves as the primary filter for identifying high-potential research projects that align with the organization’s mission to fund stage IV metastatic research.
The Surge in Translational Research Interest
Perhaps the most striking statistic shared by Dr. Shanahan is that three-quarters of all LoIs submitted for the upcoming cycle are for the $450,000 translational award. Translational research is often described as the "bench-to-bedside" bridge. It focuses on taking fundamental scientific discoveries—often made in a lab setting—and moving them into clinical applications that can directly benefit patients.
The preference for this specific award mechanism highlights a critical shift in the oncology research community. Scientists are increasingly focused on projects that have a clear path to human application, moving beyond theoretical biology toward tangible treatments. However, the high cost of these awards reflects the complexity of the work, requiring significant infrastructure, clinical coordination, and long-term data collection.
The $3.75 Million Fundraising Mandate
To sustain this level of scientific investment, the organization has announced a $3.75 million fundraising goal. While Dr. Shanahan characterized this figure as "realistic" compared to previous "lofty" aspirations, it remains an ambitious target in a post-pandemic economy. The funding is intended to cover not only the translational awards but also the administrative and peer-review infrastructure necessary to ensure that every dollar is spent on the highest-quality science.
Chronology: From Personal Trial to Philanthropic Leadership
To understand the urgency of the current grant cycle, one must look at the timeline of events that define the organization’s current trajectory. Dr. Shanahan’s own schedule serves as a microcosm of the broader struggle against metastatic disease.
The Past Eight Weeks: A Marathon of Advocacy
Over the last two months, the organizational leadership has been engaged in a relentless cycle of travel and engagement. This period included:
- Clinical Trial Participation: Dr. Shanahan herself traveled 1,100 miles each way to participate in a clinical trial. This highlights the geographic disparities in access to cutting-edge care and the personal sacrifices patients make to advance scientific knowledge.
- Scientific Conferences: Attendance at major oncology summits to stay abreast of the latest breakthroughs and to network with the researchers who will eventually apply for the 2026 grants.
- Advocacy and Policy Events: Working with legislators and other non-profits to ensure that metastatic research remains a priority on the national health agenda.
- Review Coordination: The transition from the submission of LoIs to the formal review process, which is currently underway.
The Grant Cycle Timeline
The 2026 grant cycle follows a rigorous multi-step process:
- Late 2024: Opening of the LoI submission window.
- Current Phase (Early 2025): Administrative and initial peer review of record-breaking LoI numbers.
- Mid-2025: Invitations for full proposals sent to selected researchers.
- Late 2025: Final selection and award announcements.
- 2026: Distribution of funds and commencement of research projects.
Supporting Data: The Economics of Research and Philanthropy
The decision to seek $3.75 million is backed by a complex set of data points regarding the cost of modern medical research and the changing patterns of donor behavior.
The Cost of Innovation
The $450,000 translational award is designed to cover the high overhead of clinical-grade research. According to industry standards, the cost of bringing a new drug or therapy through the early stages of a clinical trial can range from tens of thousands to millions of dollars. By offering nearly half a million dollars per grant, the organization provides "seed" funding that allows researchers to gather enough data to apply for even larger federal grants from the National Institutes of Health (NIH).
The "Coffee" Metaphor and Micro-Philanthropy
Dr. Shanahan’s call for supporters to "give up a fancy coffee" and donate reflects a growing trend in non-profit management known as micro-philanthropy. While large-scale "angel" donors are vital, the sustainability of a research organization often depends on a broad base of small-scale, recurring donors.
- Individual Impact: A $5 donation (the cost of a premium coffee) multiplied by 100,000 supporters would nearly cover a single $450,000 translational grant.
- Donor Retention: Small-scale donors who feel connected to a personal story, such as Dr. Shanahan’s airport-based advocacy, are more likely to remain loyal to the cause over multiple years.
The "Realistic" Pivot
The move toward a $3.75 million goal—described as a pivot toward realism—reflects broader economic indicators. With inflation affecting disposable income and global uncertainty impacting large-scale foundations, the organization is focusing on achievable, high-impact targets rather than over-extending its promises to the scientific community.
Official Responses: The Power of Peer Review
A cornerstone of the organization’s methodology is its unique review process, which Dr. Shanahan emphasized in her letter. The organization utilizes a dual-review system that integrates both scientific expertise and the lived experience of patients.
Scientific Reviewers: The Gatekeepers of Rigor
The record number of LoIs requires a massive mobilization of scientific reviewers. These are experts in oncology, molecular biology, and pharmacology who volunteer their time to vet the technical feasibility of the proposed projects. Their role is to ensure that the $450,000 awards are not just well-intentioned, but scientifically sound and likely to produce reproducible results.
Patient Advocate Reviewers: The "North Star" of Research
Perhaps more importantly, Dr. Shanahan highlighted the role of patient advocate reviewers. This "patient-centric" model of grant review is gaining traction across the medical field. Patient advocates ensure that the research being funded actually addresses the priorities of those living with the disease.
- Quality of Life: Advocates often prioritize research that looks at reducing side effects or maintaining long-term stability, which might be overlooked in a purely laboratory-focused review.
- Urgency: Patients bring a sense of "the ticking clock" to the review process, favoring projects that have the potential for faster clinical impact.
The official stance of the organization is clear: "We cannot do this without both scientific reviewers and patient advocate reviewers." This collaborative approach is what differentiates this funding mechanism from more traditional, bureaucratic grant processes.
Implications: What is at Stake?
The success or failure of this $3.75 million fundraising drive and the subsequent 2026 grant cycle has profound implications for the future of metastatic disease treatment.
The Future of Metastatic Research
If the goal is met, the organization will be able to fund several translational awards that could potentially unlock new treatment pathways for patients who have exhausted standard-of-care options. For many in the stage IV community, these grants represent their only hope for a "next line" of treatment.
Shifting the Philanthropic Paradigm
The emphasis on "every little bit counts" suggests a shift in how medical research is funded. By democratizing the donation process, the organization is building a community of stakeholders rather than just a list of donors. This model creates a more resilient financial base that is less susceptible to the whims of a few major contributors.
The Human Cost of Advocacy
Finally, Dr. Shanahan’s letter serves as a poignant reminder of the human cost of this work. The image of a doctor and patient leader living out of a suitcase, doing laundry between clinical trials and board meetings, underscores the exhaustion prevalent in the advocacy community. The implication is that the burden of funding research often falls on the very people who are fighting for their lives.
As the 2026 grant cycle moves into its next phase, the eyes of the oncology community remain on the $3.75 million target. Whether through the sacrifice of a "fancy coffee" or the rigorous analysis of a translational LoI, the organization is moving forward with a singular focus: transforming research from a distant hope into a living reality.
About the Author
